Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin.
Penicillin has been the mainstay of treatment for meningococcal disease. Isolates of Neisseria meningitidis that are less susceptible to penicillin have been reported in several countries and in recent years have become more common. The clinical significance of this reduced susceptibility has not been investigated on a large scale. Hence, N. meningitidis isolates from culture-confirmed cases of meningococcal disease in England and Wales, between 1993 and 2000, were routinely serogrouped, serotyped and tested for susceptibility to penicillin. These data were linked to death registrations and analysed retrospectively. The changing trends in susceptibility were described and multivariate logistic regression was used to examine associations between strain characteristics and fatal outcome. The frequency of N. meningitidis isolates less susceptible to penicillin increased from < 6% in 1993 to > 18% in 2000. In particular, isolates expressing serogroup C with serotype 2b and serogroup W135 had a higher frequency of reduced penicillin susceptibility (49% and 55%, respectively). There was no evidence of an association between fatal outcome and infection with a less penicillin-susceptible isolate. Fatal outcome was associated with serogroup and serotype, with the odds of death for cases infected with C:2a and B:2a strains three-fold higher when compared with the baseline. For this large dataset the serogroup and serotype of the infecting strain influenced mortality from meningococcal disease and may be markers for hypervirulence. No association was found between reduced penicillin susceptibility and fatal outcome, but the increasing frequency of isolates less susceptible to penicillin highlights the need for continued surveillance.
Trotter
Caroline L
CL
Fox
Andrew J
AJ
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London and *PHLS Meningococcal Reference Unit, Manchester, UK.
Ramsay
Mary E
ME
Sadler
Francesca
F
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London and *PHLS Meningococcal Reference Unit, Manchester, UK.
Gray
Stephen J
SJ
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London and *PHLS Meningococcal Reference Unit, Manchester, UK.
Mallard
Richard
R
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London and *PHLS Meningococcal Reference Unit, Manchester, UK.
Kaczmarski
Edward B
EB
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London and *PHLS Meningococcal Reference Unit, Manchester, UK.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D004739:England / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000188:drug therapy / Q000382:microbiology* / Q000401:mortality*; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000145:classification / Q000302:isolation & purification; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance; D010641:Phenotype; D012703:Serotyping; D014852:Wales / Q000453:epidemiology
D010400:Penicillin G